0.8596 -0.007 (-0.8%) | 07-26 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 2.23 ![]() |
1-year : | 3.02 ![]() |
Resists | First : | 1.91 ![]() |
Second : | 2.58 ![]() |
Pivot price | 0.95 ![]() |
|||
Supports | First : | 0.81 | Second : | 0.67 |
MAs | MA(5) : | 0.86 ![]() |
MA(20) : | 1 ![]() |
MA(100) : | 1.77 ![]() |
MA(250) : | 3.11 ![]() |
|
MACD | MACD : | -0.2 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 11.6 ![]() |
D(3) : | 11.1 ![]() |
RSI | RSI(14): 37 ![]() |
|||
52-week | High : | 10.93 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALUR ] has closed above bottom band by 23.8%. Bollinger Bands are 65.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.9 - 0.9 | 0.9 - 0.91 |
Low: | 0.83 - 0.84 | 0.84 - 0.84 |
Close: | 0.85 - 0.86 | 0.86 - 0.87 |
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
Tue, 16 Jul 2024
Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024 - Business Wire
Fri, 12 Jul 2024
Allurion Technologies Inc. (NYSE:ALUR) Short Interest Up 93.9% in June - MarketBeat
Mon, 24 Jun 2024
Allurion Technologies: Study Results Cause Rally, But I'm Awaiting 2024 FDA Catalyst - Seeking Alpha
Fri, 14 Jun 2024
Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy - Nasdaq
Tue, 11 Jun 2024
Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Tue, 14 May 2024
Allurion Technologies Inc. (ALUR) Q1 2024 Earnings Call Transcript - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 64 (M) |
Shares Float | 35 (M) |
Held by Insiders | 18.5 (%) |
Held by Institutions | 19.1 (%) |
Shares Short | 1,020 (K) |
Shares Short P.Month | 594 (K) |
EPS | -1.23 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -1.38 |
Profit Margin | -117.4 % |
Operating Margin | -121.4 % |
Return on Assets (ttm) | -81.2 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | -33.3 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.75 |
EBITDA (p.s.) | -1.18 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -62 (M) |
Levered Free Cash Flow | -36 (M) |
PE Ratio | -0.71 |
PEG Ratio | 0 |
Price to Book value | -0.63 |
Price to Sales | 1.13 |
Price to Cash Flow | -0.89 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |